文献速递肾移植

扩大标准供肾移植中机器灌注与冷保存的中期效果比较:一项队列研究

Comparison of machine perfusion versus cold storage in kidney transplant recipients from expanded criteria donors: a cohort-based study.
PubMed 文献 · Nephrol Dial Transplant · 2020-01-01

该研究基于法国DIVAT观察性队列,纳入2019例接受扩大标准供肾(ECD)的首次或二次肾移植患者,比较低温机器灌注(HMP)与静态冷保存(SCS)的中期效果。结果显示HMP组带功能生存期平均5.7年(95%CI 5.4-6.1),SCS组为6.0年(95%CI 5.7-6.2),在供体年龄≥70岁或冷缺血时间≥18小时亚组中结果相当。研究认为HMP改善中期移植物和患者生存的效用受到挑战,但短期结局改善无可争议。

要点

  • HMP与SCS的中期带功能生存期相当,HMP组5.7年 vs SCS组6.0年。
  • 在供体年龄≥70岁或冷缺血时间≥18小时亚组中,两组中期结果仍可比。
  • HMP对短期结局的改善明确,但需继续技术创新以获得长期获益证据。

核心结论

  • 在ECD肾移植中,HMP与SCS的中期患者和移植物生存率相当,挑战了HMP改善中期结局的效用。
  • HMP对短期结局的改善无可争议,但仍需技术创新以获得长期结果。

研究设计与样本

  • 基于法国DIVAT观察性队列的 cohort-based 研究。
  • 纳入2010年以来接受ECD供肾的首次或二次移植、年龄≥45岁的患者2019例,SCS组1073例,HMP组946例。
  • 采用倾向评分加权的Cox模型和Kaplan-Meier估计分析事件时间。

主要发现

  • HMP组带功能生存期平均5.7年(95%CI 5.4-6.1),SCS组6.0年(95%CI 5.7-6.2),随访至移植后8年。
  • 在供体年龄≥70岁的患者和冷缺血时间≥18小时的移植中,中期结果可比。

临床怎么用

  • 对于ECD供肾,不应仅期望通过HMP改善中期患者和移植物生存。
  • HMP仍可考虑用于改善短期结局,但需权衡中期获益的不确定性。

局限性

  • 研究为观察性队列,可能存在未测量混杂。
  • 随访时间限于移植后8年,长期结果未知。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Most studies comparing the efficacy of hypothermic machine perfusion (HMP) versus static cold storage (SCS) are based on short-term outcomes. We aimed to better evaluate the mid-term impact of HMP in patients receiving expanded criteria donor (ECD) kidneys. METHODS: The analyses were based on the French Données Informatisées et VAlidées en Transplantation (DIVAT) observational cohort. Patients aged ≥45 years transplanted for the first or second times from an ECD donor since 2010 were studied. Our study reported the graft and/or patient survivals and the incidence of acute rejection episode. The Cox models and the Kaplan-Meier estimators, weighted on the propensity score, were used to study the times-to-events. RESULTS: Among the 2019 included patients, 1073 were in the SCS group versus 946 in the HMP group. The mean life expectancy with functioning graft was 5.7 years [95% confidence interval (CI) 5.4-6.1] for the HMP cohort followed-up for 8 years post-transplantation versus 6.0 years (95% CI 5.7-6.2) for the SCS group. These mid-term results were comparable in the patients receiving grafts from donors aged ≥70 years and in the transplantations with cold ischaemia time ≥18 h. CONCLUSIONS: Our study challenges the utility of using HMP to improve mid-term patient and graft survival. Nevertheless, the improvement of the short-term outcomes is indisputable. It is necessary to continue technological innovations to obtain long-term results.

来源:Nephrol Dial Transplant,查看原文。版权归原作者所有。

引用

  1. Foucher Y, Fournier MC, Legendre C, et al. Comparison of machine perfusion versus cold storage in kidney transplant recipients from expanded criteria donors: a cohort-based study. Nephrol Dial Transplant. 2020. PMID: 32516809. doi:10.1093/ndt/gfz175

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。